Clinical Trial Update: Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) [Phase 1]

View source ↗

Summary

This clinical trial entry reports on ANGELICA, a Phase 1 study of allogeneic NKG2D ligand-targeting CAR γδ T cells (CTM-N2D) in patients with advanced cancers; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• CTM-N2D

Snippet

Sponsor: CytoMed Therapeutics Pte Ltd | Conditions: Cancer, Malignancy | Phase 1 | Status: RECRUITING